Cutaneous Lupus Erythematosus (CLE) Symptoms, Doctors, Treatments, Advances & More

Learn About Cutaneous Lupus Erythematosus (CLE)

What is the definition of Cutaneous Lupus Erythematosus (CLE)?

Cutaneous lupus erythematosus is a skin condition that usually occurs in individuals with systemic lupus erythematosus (SLE) but may appear before the disease becomes systemic. Systemic lupus erythematosus is an autoimmune disease in which the immune system attacks the skin, joints, kidneys, brain, and other organs. Cutaneous lupus erythematosus is categorized into three types: chronic cutaneous lupus erythematosus (CCLE), also known as discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), and acute cutaneous lupus erythematosus (ACLE).

Save information for later

What are the symptoms of Cutaneous Lupus Erythematosus (CLE)?

Symptoms of chronic cutaneous lupus erythematosus, also known as discoid lupus erythematosus, are the appearance of disc-like lesions on the skin that are thick, scaly, block hair follicles, appear on skin exposed to the sun, and cause scarring. Symptoms of subacute cutaneous lupus erythematosus are the appearance of thick, scaly lesions on the skin that do not scar. Symptoms of acute cutaneous lupus erythematosus are lesions on the skin that are triggered by sun exposure.

Not sure about your diagnosis?

Check Your Symptoms

What are the current treatments for Cutaneous Lupus Erythematosus (CLE)?

Treatment for chronic cutaneous lupus erythematosus, also known as discoid lupus erythematosus, involves avoiding sun exposure; wearing Helioplex sunscreen with an SPF of 70 or higher; corticosteroid creams, ointments, and injections; anti-malarial medications, such as Plaquenil, hydroxychloroquine, or chloroquine; and/or immunosuppressive medications. Treatment for subacute cutaneous lupus erythematosus includes the use of sunscreen, wearing protective clothing when in the sun, and avoiding sun exposure. Subacute cutaneous lupus erythematosus is often resistant to treatment with steroids or anti-malarial medications. Acute cutaneous lupus erythematosus may be treated with prednisone or other immunosuppressive drugs, such as methotrexate, cyclosporine, azathioprine, or myco-phenolate mofetil.

Who are the top Cutaneous Lupus Erythematosus (CLE) Local Doctors?

Dr. Victoria P. Werth

Dermatology

Elite

Highly rated in

conditions

Dermatology

Penn Medicine

Corporal Michael J Crescenz VA Medical Center

3900 Woodland Ave,

Philadelphia, PA

Victoria Werth is a Dermatologist in Philadelphia, Pennsylvania. Werth has been practicing medicine for over 43 years and is rated as an Elite expert by MediFind in the treatment of Cutaneous Lupus Erythematosus (CLE). She is also highly rated in 33 other conditions, according to our data. Her top areas of expertise are Cutaneous Lupus Erythematosus (CLE), Dermatomyositis, Discoid Lupus Erythematosus (DLE), and Pemphigus. She is board certified in Dermatology - Dermatopathology, 1989, Dermatology, 1986, and Internal Medicine, 1983 and licensed to treat patients in Pennsylvania. Werth is currently accepting new patients.

Dr. Benjamin F. Chong

Dermatology

Elite

Highly rated in

conditions

Dermatology

Dermatology Clinic At Professional Office Building 2

5939 Harry Hines Blvd,

Dallas, TX

Benjamin Chong is a Dermatologist in Dallas, Texas. Chong has been practicing medicine for over 19 years and is rated as an Elite expert by MediFind in the treatment of Cutaneous Lupus Erythematosus (CLE). He is also highly rated in 10 other conditions, according to our data. His top areas of expertise are Cutaneous Lupus Erythematosus (CLE), Discoid Lupus Erythematosus (DLE), Systemic Lupus Erythematosus (SLE), and Psoriasis. He is licensed to treat patients in Texas. Chong is currently accepting new patients.

Learn about our expert tiers

Learn more

Dr. Joseph F. Merola

Dermatology | Rheumatology

Elite

Highly rated in

conditions

Dermatology
Rheumatology

Brigham Health

Brigham And Women's Hospital, Division Of Rheumatology, Immunology And Allergy

60 Fenwood Rd,

Boston, MA

Joseph Merola is a Dermatologist and a Rheumatologist in Boston, Massachusetts. Merola has been practicing medicine for over 18 years and is rated as an Elite expert by MediFind in the treatment of Cutaneous Lupus Erythematosus (CLE). He is also highly rated in 43 other conditions, according to our data. His top areas of expertise are Psoriasis, Psoriatic Arthritis, Discoid Lupus Erythematosus (DLE), Cutaneous Lupus Erythematosus (CLE), and Gastric Bypass. He is licensed to treat patients in Massachusetts. Merola is currently accepting new patients.

View All Doctors

What are the latest Cutaneous Lupus Erythematosus (CLE) Clinical Trials?

A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients With Systemic Lupus Erythematosus and Active Cutaneous Lupus Erythematosus

Enrollment Status: Not yet recruiting

Publish Date: December 14, 2022

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.

Match to trials

Find the right clinical trials for you in under a minute

Get started

A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Enrollment Status: Recruiting

Publish Date: December 09, 2022

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

Summary: The primary objectives of the study are to evaluate the efficacy of BIIB059 compared with placebo in reducing skin disease activity measured by the Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) score [Parts A and B (US)] and the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score [Part B (ROW)] in participants with active SCLE and/...

View All Clinical Trials

What are the Latest Advances for Cutaneous Lupus Erythematosus (CLE)?